Unknown

Dataset Information

0

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.


ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we here designed, optimized, and developed an AAV-based vaccines (including AAV-RBD(max), AAV-RBD(wt), AAV-2xRBD, and AAV-3xRBD) that elicit strong immune responses against the RBD domain of the SARS-CoV-2 S protein. These immunogenic responses have proven long-lived, with near peak levels for at least six months in mice. Notably, the sera immunized with AAV-3xRBD vaccine contains powerful neutralizing antibodies against the SARS-CoV-2 pseudovirus. Further evidence proven that potent specific antibodies could also be elicited in canines after vaccination with AAV-3xRBD vaccine.

SUBMITTER: Liu F 

PROVIDER: S-EPMC8769940 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

An AAV vaccine targeting the RBD of the SARS-CoV-2 S protein induces effective neutralizing antibody titers in mice and canines.

Liu Fei F   Feng Canbin C   Xu Shiqi S   Wu Qiang Q   Tang Jian J   Chen Yan Y   Xu Ruisheng R   Chen Fuliang F   Gao Ni N   Xu Zhengzheng Z   Gu Shihui S   Lan Yang Y   Zhou Haibo H   Hu Xinde X   Wang Xiaojing X  

Vaccine 20220120 9


The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has resulted in catastrophic damage worldwide. Accordingly, the development of powerful, safe, easily accessible vaccines with long-term effectiveness is understood as an urgently needed countermeasure against this ongoing pandemic. Guided by this strong promise of using AAVs, we here designed, optimized, and developed an AAV-based vaccines (including AAV-RBD(max), AAV-RBD(wt),  ...[more]

Similar Datasets

| S-EPMC5548390 | biostudies-literature
| S-EPMC7691975 | biostudies-literature
| S-EPMC10610638 | biostudies-literature
| S-EPMC7347890 | biostudies-literature
| S-EPMC9473567 | biostudies-literature
| S-EPMC8898337 | biostudies-literature
| S-EPMC7303014 | biostudies-literature
| S-EPMC2674935 | biostudies-literature
| S-EPMC9659643 | biostudies-literature
| S-EPMC10287699 | biostudies-literature